BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, May 25, 2026
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

March 4, 2020

View Archived Issues
3-4-Biofourmis-Biovitals-Sentinel.png

Biofourmis’ AI remote monitoring platform deployed in Hong Kong COVID-19 program

In an effort to gain new insights about the novel coronavirus sweeping the globe, Boston-based Biofourmis Inc. is leveraging its artificial intelligence (AI)-driven remote monitoring platform to monitor Hong Kong patients diagnosed or suspected of having COVID-19. The remote monitoring and disease surveillance program, which kicked off just a few days ago, is being administered by the University of Hong Kong and includes Biofourmis’ Hong Kong-based joint venture, Harmony Medical Inc. Read More
Liver-doctor

Roche scores breakthrough device designation for Elecsys GALAD score

With an eye toward helping those with early stage hepatocellular carcinoma (HCC), Basel, Switzerland-based Roche Group has won a breakthrough device designation from the U.S. FDA for the Elecsys GALAD score. When combined with ultrasound, the Elecsys GALAD score aims to help provide more accurate information for clinicians to treat patients at an earlier stage. Read More
Capitol2.png

DeLauro says House, Senate leaders agree on coronavirus supplemental

The March 4 congressional hearing on the budget for the NIH was peppered with questions about the COVID-19 outbreak, although the general sentiment is that the agency will receive yet another boost in appropriations in fiscal 2021. Read More
asia-japan-flag.png

Japan’s medical device price cut set to be smaller in 2020

HONG KONG – Japan cuts medical device prices every two years to manage increasing health care costs. This year, the biennial medical device price cut will take effect beginning on April 1, 2020. Read More
3-4-Physiq.png

Physiq AI platform gives advance notice of up to 10 days of impending heart failure crisis

An artificial intelligence (AI) platform developed by Naperville, Ill.-based Physiq Inc. gave researchers a mean of 10.4 days warning of an impending heart failure exacerbation that would require hospitalization or an emergency department visit, according to a study published in Circulation – Heart Failure. Read More
Tau neuron illustration

Tau protein plays role in autism spectrum disorder

Lowering levels of tau protein improved multiple symptoms of autism spectrum disorders (ASD) in two different mouse models of the disease, both of which are driven by hyperactivity of the mTOR PI3 kinase pathway. Read More

Appointments and advancements for March 4, 2020

New hires and promotions in the med-tech industry, including: Anika Therapeutics, Charles River Laboratories International, Citiustech. Read More

Financings for March 4, 2020

Med-tech firms raising money in public or private financings, including: Nanostring Technologies. Read More

In the clinic for March 4, 2020

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Inflammatix, Ocutrx Vision Technologies. Read More

Other news to note for March 4, 2020

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Allscripts, Biogen, Celgene, Emovi, Genentech, Haliodx, Immunxperts, Kabafusion, Lincare, Luminex, Lung Therapeutics, Macopharma, Mahajan Imaging, Medical 2011, Medx Health, Mesa Biotech, Nexelis, Optikira, Orthopediatrics, Pixium Vision, Pliant Therapeutics, Respivant Sciences, SymphonyAI, SyntheticMR, Terarecon, Veradigm. Read More

Regulatory actions for March 4, 2020

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Roche. Read More

Regulatory front for March 4, 2020

The latest global regulatory news, changes and updates affecting medical devices and technologies, including: American Clinical Laboratory Association, DNA Technologies, Texas Instruments, Dialog Semiconductors, Telink Semiconductors. Read More

BioWorld MedTech’s Orthopedics Extra for March 4, 2020

Keeping you up to date on recent developments in orthopedics, including: Researchers identify protein critical for wound healing after spinal cord injury; Journal publishes results of Gid Bio trial for treating osteoarthritis knee pain; Study maps landmarks of peripheral artery disease to guide treatment development. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 22, 2026.
  • Brain and DNA

    Sangamo presents primate data for prion suppressor ST-506

    BioWorld Science
    Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
  • TREM2 agonists detailed in Pfizer patent

    BioWorld Science
    Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
  • Red dart and target against blue sky

    Unmasking the X: EPAC2 shifts the fragile X landscape

    BioWorld
    Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
  • Skin irritation on hands

    Recludix presents STAT1/3 inhibitors for dermatological diseases

    BioWorld Science
    Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing